Article Information
History
- July 26, 2016.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chris Finan1,3,†,
- Anna Gaulton2,†,
- Felix. A Kruger1,3,
- Tom Lumbers1,3,
- Tina Shah1,3,
- Jorgen Engmann1,3,
- Luana Galver5,
- Ryan Kelley5,
- Anneli Karlsson2,
- Rita Santos2,6,
- John P. Overington2,4,*,
- Aroon D. Hingorani1,3,* and
- Juan P. Casas3,*,†
- 1Institute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT
- 2European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom
- 3Farr Institute in London, Institute of Health Informatics, University College London, London WC1E 6BT
- 4Stratified Medical, 40 Churchway, London, UK
- 5Illumina Inc, 5200 Illumina Way, San Diego, CA 92122 USA
- 6GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, United Kingdom. (current address)
- ↵* Corresponding authors - John Overington: john.overington{at}stratifiedmedical.com, Aroon Hingorani: a.hingorani{at}ucl.ac.uk, Juan Casas: jp.casas{at}ucl.ac.uk.
↵† Authors contributed equally.
Posted July 26, 2016.
The druggable genome and support for target identification and validation in drug development
